US2010324099A1PendingUtilityA1

Sustained release aminopyridine compositions

61
Assignee: BLIGHT ANDREW RPriority: Dec 11, 2003Filed: Jun 25, 2010Published: Dec 23, 2010
Est. expiryDec 11, 2023(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/00A61P 25/28A61P 19/00A61K 31/4409A61K 9/2054A61K 31/44A61K 9/2077A61K 47/12A61K 47/44A61K 47/14A61K 47/38A61K 9/20
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Claims

exact text as granted — not AI-modified
1 . A method to decrease a symptom associated with a neurological disorder by use of 4-aminopyridine, as set forth herein. 
     
     
         2 . A method of using 4-aminopyridine to normalize a body function that has been impaired by a neurological disorder, as set forth herein. 
     
     
         3 . A method to provide improvement in one or more of the clinically measured parameters associated with a neurological disorder, by use of 4-aminopyridine as set forth herein.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.